利妥昔单抗（美罗华）。
Rituximab (Rituxan).
机构信息
Division of Pediatric Nephrology, University of Michigan Mott Children's Hospital, Ann Arbor, Michigan, USA.
出版信息
AJNR Am J Neuroradiol. 2010 Aug;31(7):1178-80. doi: 10.3174/ajnr.A2142. Epub 2010 May 6.
Abstract
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
摘要
利妥昔单抗是一种单克隆抗体，最初被 FDA 批准为一种抗肿瘤药物，旨在治疗 B 细胞恶性肿瘤。本文将回顾这种抗 B 细胞药物的作用机制和临床作用。
相似文献
1
Rituximab (Rituxan).利妥昔单抗（美罗华）。
AJNR Am J Neuroradiol. 2010 Aug;31(7):1178-80. doi: 10.3174/ajnr.A2142. Epub 2010 May 6.
2
Rituximab: ongoing and future clinical development.利妥昔单抗：正在进行的及未来的临床开发
Semin Oncol. 2002 Feb;29(1 Suppl 2):105-12.
3
Rituximab-induced tumor progression: does it really happen?利妥昔单抗诱导的肿瘤进展：真的会发生吗？
Med Oncol. 2004;21(2):205-6. doi: 10.1385/MO:21:2:205.
4
Impact of maintenance rituximab in patients with transformed indolent B cell lymphoma.美罗华维持治疗对转化型惰性B细胞淋巴瘤患者的影响
Leuk Lymphoma. 2020 Dec;61(12):2985-2989. doi: 10.1080/10428194.2020.1789631. Epub 2020 Jul 6.
5
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.利妥昔单抗维持治疗高肿瘤负荷的初治惰性B细胞非霍奇金淋巴瘤的日本II期研究。
Int J Hematol. 2016 Dec;104(6):700-708. doi: 10.1007/s12185-016-2097-9. Epub 2016 Oct 6.
6
Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.利妥昔单抗（嵌合抗CD20抗体）的同型二聚体而非单体可诱导人B淋巴瘤细胞凋亡，并与化疗药物和免疫毒素协同作用。
Blood. 2001 Mar 1;97(5):1392-8. doi: 10.1182/blood.v97.5.1392.
7
Use of rituximab, the new FDA-approved antibody.使用利妥昔单抗，这是一种新获得美国食品药品监督管理局批准的抗体。
Curr Opin Oncol. 1998 Nov;10(6):548-51. doi: 10.1097/00001622-199811000-00012.
8
Rituximab in space: intrapleural and other novel routes of administration for lymphomas and lymphoid leukemias.利妥昔单抗在空间中的应用：胸膜内及其他用于淋巴瘤和淋巴细胞白血病的新型给药途径。
Leuk Lymphoma. 2012 Jan;53(1):5-7. doi: 10.3109/10428194.2011.615428. Epub 2011 Sep 29.
9
Clinical status and optimal use of rituximab for B-cell lymphomas.利妥昔单抗在B细胞淋巴瘤中的临床状况及最佳应用
Oncology (Williston Park). 1998 Dec;12(12):1763-9; discussion 1769-70, 1775-7,.
10
Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas.胸膜内注射利妥昔单抗治疗B细胞淋巴瘤所致恶性胸腔积液。
Leuk Lymphoma. 2012 Jan;53(1):156-7. doi: 10.3109/10428194.2011.602769. Epub 2011 Aug 18.
引用本文的文献
1
Improving recombinant antibody production using FcBAR: An in situ approach to detect and amplify protein-protein interactions.使用FcBAR改善重组抗体生产：一种检测和放大蛋白质-蛋白质相互作用的原位方法。
Metab Eng. 2025 Jul 23;92:174-184. doi: 10.1016/j.ymben.2025.07.006.
2
Improving Recombinant Antibody Production Using FcBAR: An In Situ Approach to Detect and Amplify Protein-Protein Interactions.使用FcBAR改善重组抗体生产：一种检测和放大蛋白质-蛋白质相互作用的原位方法。
bioRxiv. 2025 Jun 17:2025.06.12.659199. doi: 10.1101/2025.06.12.659199.
3
Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.利妥昔单抗治疗依赖类固醇且频繁复发的成人肾病综合征的长期疗效
BMC Nephrol. 2025 Mar 6;26(1):126. doi: 10.1186/s12882-025-04035-0.
4
Preclinical Aspects of [Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging.[锆]锆-去铁胺-利妥昔单抗的临床前研究：一种用于免疫正电子发射断层显像的高潜力药物。
Curr Radiopharm. 2025;18(2):131-140. doi: 10.2174/0118744710326742241018050220.
5
Clinical advances in immunotherapy for immune-mediated glomerular diseases.免疫介导性肾小球疾病免疫治疗的临床进展。
Clin Exp Med. 2023 Dec;23(8):4091-4105. doi: 10.1007/s10238-023-01218-7. Epub 2023 Oct 27.
6
Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.利妥昔单抗与坏疽性脓皮病：利用系统生物学信息方法对FAERS数据库中的不成比例性进行调查
Drugs Real World Outcomes. 2022 Dec;9(4):639-647. doi: 10.1007/s40801-022-00322-6. Epub 2022 Aug 6.
7
Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes.利妥昔单抗对嘌呤霉素诱导的人足细胞凋亡、黏附丧失和细胞骨架改变的保护作用。
Sci Rep. 2022 Jul 19;12(1):12297. doi: 10.1038/s41598-022-16333-w.
8
Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?利妥昔单抗用于成人激素依赖型微小病变病：是时候做出改变了吗？
Cureus. 2022 Feb 17;14(2):e22313. doi: 10.7759/cureus.22313. eCollection 2022 Feb.
9
Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination.利妥昔单抗诱导的新冠病毒疫苗接种后急性淋巴细胞溶解和全血细胞减少症
Clin Case Rep. 2021 Aug 16;9(8):e04517. doi: 10.1002/ccr3.4517. eCollection 2021 Aug.
10
Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.适用于非霍奇金淋巴瘤的可适应性抗体纳米蠕虫。
Biomaterials. 2020 Dec;262:120338. doi: 10.1016/j.biomaterials.2020.120338. Epub 2020 Aug 31.
本文引用的文献
1
Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.三名自身免疫性血细胞减少症患儿接受利妥昔单抗治疗后抗体持续耗竭。
Pediatr Hematol Oncol. 2009 Nov;26(8):566-72. doi: 10.3109/08880010903271697.
2
Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection.接受利妥昔单抗治疗体液性肾移植排斥反应的患者发生迟发性肺孢子菌肺炎。
Nephrology (Carlton). 2009 Oct;14(7):696-9. doi: 10.1111/j.1440-1797.2009.01168.x.
3
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.利妥昔单抗、那他珠单抗和依法珠单抗治疗患者中与单克隆抗体相关的进行性多灶性白质脑病：药物不良事件和报告研究（RADAR）项目的综述
Lancet Oncol. 2009 Aug;10(8):816-24. doi: 10.1016/S1470-2045(09)70161-5.
4
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.利妥昔单抗，一种抗CD20单克隆抗体：历史与作用机制
Am J Transplant. 2006 May;6(5 Pt 1):859-66. doi: 10.1111/j.1600-6143.2006.01288.x.
5
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.利妥昔单抗（抗CD20单克隆抗体）在类风湿关节炎患者II期临床试验中的群体药代动力学。
J Clin Pharmacol. 2005 Jul;45(7):792-801. doi: 10.1177/0091270005277075.
6
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.环磷酰胺、长春新碱、泼尼松（CVP）化疗联合利妥昔单抗与单纯CVP作为晚期滤泡性淋巴瘤一线治疗方案的比较
Blood. 2005 Feb 15;105(4):1417-23. doi: 10.1182/blood-2004-08-3175. Epub 2004 Oct 19.
7
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.利妥昔单抗靶向B细胞治疗对类风湿关节炎患者的疗效。
N Engl J Med. 2004 Jun 17;350(25):2572-81. doi: 10.1056/NEJMoa032534.
8
Clinical use of rituximab in haematological malignancies.利妥昔单抗在血液系统恶性肿瘤中的临床应用。
Br J Cancer. 2003 Oct 20;89(8):1389-94. doi: 10.1038/sj.bjc.6601187.
9
Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab.大剂量化疗联合自体血干细胞挽救及移植前利妥昔单抗治疗后出现的罕见病毒感染（进行性多灶性白质脑病和巨细胞病毒病）
Blood. 2002 Feb 15;99(4):1486-8. doi: 10.1182/blood.v99.4.1486.
10
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.老年弥漫性大B细胞淋巴瘤患者中，CHOP化疗联合利妥昔单抗与单纯CHOP化疗的比较。
N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.
Zotero 插件